Ruth Devenyns, Precirix CEO
March 16, 2022 10:45 AM EDT
Financing

Biotech up­start rides the up­surge in ra­dio­phar­ma R&D to $88M round with mar­quee in­vestors

Paul Schloesser

Associate Editor

Bel­gian biotech up­start Pre­cir­ix had raised $40 mil­lion in a Se­ries A from 6 VC back­ers four years ago. Now, all of those in­vestors have …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

A VC-backed ge­net­ic test­ing start­up to 'con­sid­er' mak­ing an of­fer to buy 23andMe

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times